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Abstract
Our aim is to assess the safety and potential efficacy of a novel treatment paradigm in pulmonary arterial hypertension (PAH),
immunomodulation by blocking interleukin-6 (IL6) signaling with the IL6 receptor antagonist, tocilizumab. Inflammation and
autoimmunity are established as important in PAH pathophysiology. One of the most robust observations across multiple cohorts
in PAH has been an increase in IL6, both in the lung and systemically. Tocilizumab is an IL-6 receptor antagonist established as safe
and effective, primarily in rheumatoid arthritis, and has shown promise in scleroderma. In case reports where the underlying cause
of PAH is an inflammatory process such as systemic lupus erythematosus, mixed connective tissue disease (MCTD), and
Castleman’s disease, there have been case reports of regression of PAH with tocilizumab. TRANSFORM-UK is an open-label
study of intravenous (IV) tocilizumab in patients with group 1 PAH. The co-primary outcome measures will be safety and the
change in resting pulmonary vascular resistance (PVR). Clinically relevant secondary outcome measurements include 6-minute walk
distance, WHO functional class, quality of life score, and N-terminal pro-brain natriuretic peptide (NT-proBNP). If the data support
a potentially useful therapeutic effect with an acceptable risk profile, the study will be used to power a Phase III study to properly
address efficacy.
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Introduction
Pulmonary arterial hypertension (PAH) comprises a group
of orphan diseases historically associated with a poor prog-
nosis. In the last 20 years, four classes of drug therapy tar-
geting vasoactive pathways have been studied in randomized
controlled trials (RCTs) and licensed for the treatment of
predominantly group 1 PAH. These therapies have demon-
strated moderate success, with meta-analyses of all RCT
data suggesting a short-term improvement in mortality at
14 weeks.1 Despite this, PAH in the UK still carries a five-
year survival in idiopathic PAH (IPAH) of 61%2 and as low
as 49% for PAH associated with connective tissue
diseases.3,4 Therefore, there remains an urgent need for the
development of new treatments, particularly as the results
from combination studies of these different classes of vaso-
active therapies has been, to date, mixed and disappointing.5
The strong association of PAH with dysregulated immunity
and inflammation has been long established with auto-
immune diseases,6 most prominently scleroderma, but also not-
ably rheumatoid arthritis (RA), systemic lupus erythematosus
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(SLE), mixed connective tissue disease (MCTD), and Sjogren’s
syndrome.7 Auto-immune diseases, in particular, are therefore
recognized as causally associated with PAH, but there is also
an association of the idiopathic form of PAH (IPAH) with
auto-immune thyroid disease, links to HLA subtypes8 and the
presence of auto-antibodies in up to 93% of patients.9,10 IPAH
has previously been speculated historically to be an auto-
immune disease.11 More locally, within the pulmonary
vascular lesions, there is accumulation of inflammatory cells
including T and B lymphocytes12 with altered T regulatory cell
function13,14 and changes in B cell gene expression.15 It is clear,
therefore, that inflammation and dysregulated immunity play
a significant role in a spectrum of causes of PAH. From the
perspective of identifying pathways that are targetable, IL-6
has emerged as a strong candidate. IL-6 has been well-char-
acterized as raised in peripheral blood and within the lung in
PAH12,16 and is an independent marker of prognosis outper-
forming traditional markers of cardiac function such as NT-
proBNP.17 Over-expression of IL-6 in animal models using
transgenic mice leads to pulmonary hypertension18 and in hyp-
oxia, IL-6 deficient mice are protected.19 Administration of
recombinant IL-6 to rats also recapitulates a PAH pheno-
type.20 Tocilizumab is an IL-6 receptor antagonist established
as safe, well tolerated, and effective, primarily in RA,21 and
has shown promise in scleroderma.22 In uncommon cases,
where the underlying cause of PAH is an established inflam-
matory process such as SLE, MCTD, and Castleman’s dis-
ease, there have been case reports of regression of PAH with
tocilizumab.23–25 We therefore propose a phase II open-label
proof of concept study of tocilizumab in group I PAH.
Hypothesis
Immunomodulation utilizing interleukin-6 (IL6) receptor antag-
onism is a novel treatment strategy for patients with group 1
PAH and will improve pulmonary hemodynamic parameters.
Methods
Study participants
Patients will be recruited from seven adult specialist PH cen-
ters in the UK: Papworth Hospital, Cambridge; Golden
Jubilee Hospital, Glasgow; Freeman Hospital, Newcastle;
Royal Hallamshire, Sheffield; Hammersmith Hospital,
London; Royal Brompton Hospital, London; Royal Free
Hospital, London; and Imperial College, London. We aim
to recruit 21 patients with a 15% drop-out rate and with
provision for replacement. Study entry criteria (Table 1)
and exclusion criteria (Table 2) are outlined below. Local
ethics REC number 15/EM/0401, EudraCT 2015-002799-26.
Study design rationale
We have taken a conservative safety-led open-label trial
design approach (Fig. 1). This has been driven by a safety-
first approach but also from previous trial experience in
both open-label and RCTs of the stability of PVR as a pri-
mary endpoint. Delta change in PVR over a six-month
period in phase 2 and 3 trials demonstrate little evidence
of a significant placebo response with the majority of trials
reporting a deterioration over four to six months (Fig. 2).
The timeframe of six months was informed by the duration
of clinical response in other autoimmune indications and, in
particular, RA and scleroderma.
Table 1. Inclusion criteria.
Demographics
1. Individual must be aged 18–70 years at the screening visit.
2. Individual must weigh> 40 kg at the screening visit.
PAH diagnosis and classification
1. Participants must have a diagnosis of group 1 PAH
due to the following:
 idiopathic or heritable PAH;
 PAH associated with connective tissue disease excluding SLE,
RA, mixed CTD;
 drug or toxins.
2. Individual must have a current diagnosis of being in WHO
functional class II–IV.
3. Participant must meet all of the following hemodynamic criteria
by means of a right heart catheterization before screening:
 mPAP of  25mmHg;
 PVR 300 dynes/s/cm5;
 PCWP or LVEDP of 12mmHg if PVR 300 to
< 500 dyne/s/cm5; or
 PCWP/LVEDP< 15mmHg if PVR 500 dynes/s/cm5.
4. Participant must meet all of the following pulmonary function
tests completed no more than 24 weeks before the screening visit:
total lung capacity (TLC) 60% of predicted normal and forced
expiratory volume in 1 s (FEV1) 60% of predicted normal.
5. Individual must walk a distance of 100m at the screening visit.
6. Participant, with or without supplemental oxygen, must have a
resting arterial oxygen saturation (SaO2) 85% as measured by
pulse oximetry at the screening visit.
7. Individuals are required to have a documented negative V/Q
scan or pulmonary arteriogram confirming the absence of CTEPH
before screening.
General
1. Female participant of childbearing potential, if sexually active,
must agree to use two reliable methods of contraception, from the
screening visit until at least four months following the last dose of
investigational product. Individuals who have had a Copper T 380A
IUD or LNg 20 IUD inserted are not required to use additional
methods of contraception.
2. Participant must agree not to participate in a clinical study
involving another investigational drug or device throughout this
study.
3. Individual must be competent to understand the information
given in the Institutional Review Board (IRB) or Independent Ethics
Committee (IEC) approved Informed Consent Form and must sign
the form before the initiation of any study procedures.
4. Participant must be stable on an unchanged PAH therapeutic
regime for at least one month before screening.
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Recruitment
Participants will be identified using data collected during
their routine outpatient appointment at each of the pulmon-
ary hypertension centers.
Investigational product
IV therapy will be administered at a dose of 8mg/kg once
monthly for six months. Other PAH therapies may not be
added unless an individual has experienced a clinical failure
event. A clinical failure event is defined as the following:
worsening of PAH; initiation of treatment with intravenous
or subcutaneous prostanoids; lung transplantation; or atrial
septostomy or death from any cause up to the end of treat-
ment. Worsening of PAH is defined by the occurrence of all
three of the following:
. a decrease in the 6-minute walk distance (6MWD) of at
least 15% from baseline, confirmed by a second 6-minute
walk test (6MWT) performed on a different day within
two weeks;
. the need for additional treatment for PAH;
. worsening of symptoms of PAH includes at least one of
the following: a change from baseline to a higher WHO
functional class (or no change in patients who were in
WHO functional class IV at baseline) and the appearance
or worsening of signs of right heart failure that did not
respond to oral diuretic therapy.
Study assessments and procedures
Safety assessment, primary and secondary outcome data will
be undertaken as per the assessment schedule (data supple-
ment). Primary and secondary endpoints are listed below.
Primary endpoints
. Safety as defined by the incidence and severity of adverse
events
. Pulmonary vascular resistance (dynes.s/cm5) measured using
invasive hemodynamic assessment by right heart catheter
Clinical secondary endpoints
. 6MWD
. BORG dyspnea scoring index
. N-Terminal pro-B-type natriuretic peptide
. WHO functional class assessment
. Disease-specific quality of life assessment tools
Exploratory secondary endpoints
. Analysis of flow cytometric based peripheral blood leuco-
cyte immunophenotyping
. Serum and plasma measurements of circulating cytokines
Statistical considerations
This is a proof-of-concept study and the sample size has
been determined with respect to safety (in terms of exposure
Table 2. Exclusion criteria.
PAH treatments
1. Individuals on continuous infusions either intravenously or subcutaneously.
2. Patients on TNF antagonists or other biological treatments.
3. Participant has a known hypersensitivity to the investigational products,
the metabolites, or formulation excipients.
4. Individual has severe renal impairment (creatinine clearance < 30 mL/min)
at the screening visit.
Medical history/current medical conditions
1. Participant with active infection at time of screening.
2. Individuals with known hepatitis B or tuberculosis.
3. Participant has severe hepatic impairment (Child-Pugh class C with or
withoutcirrhosis) at the screening visit.
4. Patient with ALT or AST> 5 upper limit of normal.
Hematology and bleeding disorders
1. Individual has clinically significant anemia in the opinion of the
investigator, in particular from pyruvate kinase and G6PD deficiencies.
2. Participants with bleeding disorders or significant active peptic ulceration
in the opinion of the investigator.
3. Individual has peripheral blood platelets< 100 109/L.
4. Participant has a neutrophil count< 2 109/L.
Cardiovascular
1. Individual has had an acute myocardial infarction within the last 90 days
before screening.
NB: Participants must not have three or more of the following left ventricular
disease/dysfunction risk factors:
2. Body mass index (BMI) 35
3. Historical evidence of significant coronary disease established by any one of:
 history of myocardial infarction;
 history of percutaneous intervention;
 angiographic evidence of CAD (>50% stenosis in at least one vessel),
either by invasive angiography or by CT angiography;
 positive stress test with imaging (either pharmacologic or with exercise);
 previous coronary artery surgery;
 chronic stable angina.
General medical conditions
1. Individual with cardiovascular, liver, renal, hematologic, gastrointestinal,
immunologic, endocrine, metabolic, or central nervous system disease that,
in the opinion of the investigator, may adversely affect the safety of the
participant and/or efficacy of the investigational product or severely limit
the lifespan of the individual other than the condition being studied.
2. Participant has a history of malignancies within the past five years, except for
an individual with localized, non-metastatic basal cell carcinoma of the skin,
in situ carcinoma of the cervix, or prostate cancer who is not currently or
expected, during the study, to undergo radiation therapy, chemotherapy,
and/or surgical intervention, or to initiate hormonal treatment.
3. History of diverticulitis, diverticulosis requiring antibiotic treatment, or
chronic ulcerative lower GI disease such as Crohn’s disease, ulcerative col-
itis, or other symptomatic lower GI conditions that might predispose a
patient to perforations.
General criteria
1. Female participant who is pregnant or breastfeeding.
2. Individual has demonstrated non-compliance with previous
medical regimens.
3. Participant has a recent (within one year) history of abusing alcohol or
illicit drugs.
4. Individual has participated in a clinical study involving another
investigational drug or device within four weeks before the screening visit.
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to the drug and investigations) and feasibility (patient popu-
lation). We have intentionally only powered the study to
pick up large effect sizes. The primary outcome is PVR
fold change from baseline after six months of treatment,
i.e. PVR6months/PVRbaseline. Fold change is positively
skewed although assumed to be normally distributed after
a log transformation. It would be clinically significant if
PVR6months decreased by 30% from PVRbaseline, i.e.
PVR6months¼ (1–0.3) PVRbaseline. Hence, the expected fold
change is PVR6months/PVRbaseline¼ 0.7, or log(0.7)¼ 0.15
in the log scale (the sign is to make the number positive but
has no effect on sample size). The standard deviation of log
fold change after three months was 0.42. Therefore, the
sample size (n) required to detect the aforementioned log
fold change in PVR with 90% power and 5% statistical
significance was 17. Accounting for approximately 20%
of drop-outs, the final n was 21. N.B. The pwr package
in R was used with the following command: pwr.t.test
(d¼log(0.7)/0.42, sig.level¼ 0.05, power¼ 0.9, type¼
‘‘one.sample,’’ alternative¼ ‘‘two.sided’’).
Classical hypothesis testing pioneered by RA Fisher
hinges heavily on P values and rejection of a null hypothesis
(H0). Statistically, a P value is the area of a theoretical dis-
tribution of a statistic under H0 beyond an observed value
given data. Informally, a P value measures how compatible
are the observed data with H0. Traditionally, a P value
of 0.05 has been used as statistical evidence against H0,
and as a consequence, of prove of an effect. However,
Fisher never intended for it to be fixed at 5% and recom-
mended each trial to gauge an appropriate value given for
example the possible consequences of false positive findings.
In rare diseases, RCTs are always of relatively small size.
The distribution of P values under the alternative hypothesis
(H1) in trials with low power, e.g. 80%, is practically uni-
form regardless of the actual biological effect.26 This means
that a P value of 0.05 or 0.0005, i.e. 100 times lower, are
equally likely for the same effect. P values are therefore
equivocal indicators of how strong effects are unless the
power exceeds 90%. RCTs in rare diseases suffer from low
statistical power given the limitations of finding enough
patients. Under these circumstances, the Bayesian paradigm
offers an additional advantage over the frequentist one:
informative priors. In a Bayesian analysis, additional infor-
mation not contained in the data can be brought in to
enlighten the results and reduce uncertainty, unlike the clas-
sical statistical paradigm. This additional information is
called the prior and refers to the possible distributional
properties of any parameter that we may be interested in
before considering the data.
Primary Bayesian analysis
Primary outcome analysis will utilize a Bayesian analysis
with a flat prior distribution. It is reasonable to assume
that the log of PVR fold change (logPVRfc¼ log
PVR6months/PVRbaseline) follows a normal distribution with
mean m and precision  (¼ s2, which is the inverse of the
variance of the parameter). A 95% credible interval, i.e.
highest posterior density interval, for logPVRfc will be
obtained using a flat uniform prior for m ranging from
10 (fc¼ 0.00005, i.e. tocilizumab removes PVR com-
pletely) to 10 (fc¼ 22026, i.e. tocilizumab strongly aggra-
vates PVR) and a vague prior for Gamma(0.001,0.001).
In the absence of useful prior information, this choice of
priors will ensure that the data defines the posterior distri-
bution of logPVRfc.
We simulated data to show the benefits of Bayesian ana-
lysis in this small size RCT (programs provided in
Appendix). PVR before treatment was assumed to be dis-
tributed as a log-normal with mean log(300) and standard
deviation log(3), whereas PVR after treatment was assumed
to be distributed as another log-normal with mean log(200)
and sd log(2) (Fig. 3). Thirty-three percent of patients have
PVR> 500 before intervention compared to just 9% after
intervention. The average fold change was 0.94, or equiva-
lently in the log scale, 0.51. Table 3 shows Bayesian results
for log-FC given the aforementioned flat prior (equivalent
to a frequentist analysis) and an informative prior.
Here, the informative prior is obtained from the results
observed with the flat prior. This serves to illustrate an
Fig. 2. Forest plot of meta-analysis data for change in PVR in the
placebo arm of placebo controlled trials. Mean with 95% confidence
intervals.
Fig. 1. Trial design.
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advantage of incorporating good additional information in
the form of informative priors: the 95% credibility interval
(similar to the frequentist confidence interval) is narrower
when using good informative priors indicating much more
certainty around the true effect of tocilizumab. In practice,
priors cannot be obtained from a prior Bayesian analysis
under informative priors but from independent sources.
Likewise, if prior and data disagree, the credibility interval
can be larger than the confidence interval in a frequentist
analysis. This is nevertheless not a disadvantage but a real-
istic picture of the effect of combining conflicting sources of
information.
In comparison, the Wilcoxon test outputs a statistic
V¼ 183, which is not intuitive, and a P value of 0.018. It
has detected a difference at 5% significance but it does not
provide any further information into the effect of tocilizu-
mab in PVR. In contrast, the most conservative Bayesian
analysis with flat priors informs us that tocilizumab renders
on average a fold change of 0.60 (simulated value 0.67) but
that given 18 individuals and the distributions in Fig. 3 the
true effect is between 0.93 and 0.38 with 95% probability
(the range is 0.45–0.81 when using good informative priors
or a 65% reduction in the credible interval). Note that this
probability statement on intervals does not apply to the
frequentist confidence interval. There, an interval either con-
tains the true parameter value or does not, and is under-
stood in terms of what proportion of those intervals would
contain the true parameter in the long run after many hypo-
thetical experiments.
Expert prior elicitation
Fig. 4 shows all the possible results expected after complet-
ing the TRANSFORM project (www.transform-uk.com). If
we assume 21 patients completed treatment successfully and
had PVR measures at baseline and after 24 weeks, a patient
will be scored 1 if PVR reduced by at least 30% from base-
line (success), otherwise he/she will be scored as 0. The ques-
tion is: what is the probability of a successful treatment for a
random individual with group 1 PAH? The Bayesian solu-
tion to this problem is to combine prior information sum-
marizing all available knowledge of the effect of tocilizumab
in PVR among PAH patients and new data from a trial to
update our knowledge of the probability of success (P).
Unlike frequentist analysis, the Bayesian solution is a distri-
bution of possibilities for the parameter P, i.e. the posterior
distribution. For example, the top left plot in Fig. 4 shows
all the potential posterior distributions expected at the end
of the trial (when data and prior are combined) given a flat
prior, i.e. equivalent to complete uncertainty about the effect
of tocilizumab on PVR. The leftmost curve corresponds to
the distribution given 0 success and 21 failures in the study,
the next curve to the right corresponds to observing 1 suc-
cess and 20 failures in the study, and so on until the last
curve to the right which corresponds to having observed 21
successes and 0 failures. Those results would also be
obtained in a frequentist analysis where the prior is always
uninformative, i.e. only the data carry information. The
added advantage of Bayesian analysis is that a bona-fide
prior enlightened the results by reducing bias after repos-
itioning the most likely effect estimate (the mode) and redu-
cing the error or uncertainty around the most likely estimate
(reducing the width of the distribution). With a flat prior (no
knowledge about the effect of tocilizumab) and 0 successes,
the most likely probability of success is 0 (technically, the
mode does not exist but it is 0 asymptotically) and the stand-
ard error is 0.04. However, when using the expert elicited
prior and given the same experimental outcome (0 suc-
cesses), the most likely value for the probability of success
of tocilizumab is no longer 0 but 0.02 and the standard error
is 0.05. Even with no observed successes, there was still a
non-zero probability that tocilizumab may work. This state-
ment takes into account both a relatively vague expert prior
with mode at 0.2 and a small dataset (n¼ 21).
For comparison, paired changes in the primary endpoint
PVR will be assessed using the Wilcoxon signed-rank test.
(significance set at P value< 0.05). A conservative approach
to secondary endpoints will be presented with median and
confidence intervals. The actual prior elicitation produced
results shown in Fig. 5. It reveals an overall belief among
experts that tocilizumab ought to work in 20–40% of the
cases but with a non-negligible probability of not working at
all (about 10% of the overall weight falls onto no effect at
Fig. 3. Hypothetical distributions of PVR before intervention (red)
and after (green).
Table 3. Bayesian output for log-FC with two different priors.
Prior Mean SD 2.5% 50% 97.5%
Flat 0.51 0.22 0.96 0.51 0.07
Informative 0.51 0.15 0.79 0.51 0.21
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all), and a low probability (20%) that it will work more than
50% of the time.
Discussion
A trial of immunosuppression in PAH is now warranted.
Over the last 20–30 years, evidence has accumulated to sug-
gest that inflammation and autoimmunity play a role not
just in CTD but also in IPAH, though the exact role is
unclear and a significant question remains about how
much is pathogenic and how much is inflammation related
to chronic disease. The concept of immunosuppression in
other vascular diseases is gaining momentum, even in the
absence of autoimmunity. Examples of this include blocking
IL-1 in acute coronary syndromes27 and in atherosclerosis
(CANTOS study: NCT01327846). This is not to downplay
the implications. We acknowledge that to commit PAH
patients to immunosuppression is a significant undertaking
and we would not underestimate the potential effects of this.
The side effect profile of most immunosuppressive therapy is a
new area for PAH and cannot be ignored. For this reason, we
feel that immunosupression should not be considered unless it
is going to be transformative to patient outcomes. Our study
is powered for large effects only in recognition of this.
We have paradoxically excluded patients with SLE,
MCTD, and Castleman’s disease to minimize heterogeneity
Fig. 4. Posterior distributions of probability of success, i.e. tocilizumab reduced PVR at least 30% from baseline, given different priors (flat,
optimistic, pessimistic, and expert elicited).
Fig. 5. Prior expert elicitation.
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and the chance of a positive study being driven by response
in rarer diseases. Additionally, the majority of these patients
are already immunosuppressed. We believe a trial specific-
ally looking at immunosuppression in CTD-PAH is overdue
but the trial design would have to be different reflecting the
availability of licensed and established immunotherapies. A
trial only looking at these rare causes would require many
more centers. The open-label nature of our study may be
viewed as contentious. We have examined available PVR
data from recent meta-analyses1,28 and PVR is not placebo
responsive with the majority of trials reporting increases at
four to six months. Given the lack of placebo effect on PVR,
we feel the only likely impact of this therefore will be missing
signal related to participants deteriorating, and there is a
risk our study may underestimate effects. As the first trial
of a new approach, we are also aware that a valid criticism is
that we may not be enriching our trial for patients likely to
respond. Given the novelty of this approach, we have
chosen to start with patients who are relatively stable, pre-
dominantly on dual therapy and therefore a ‘‘prevalent’’ not
‘‘incident’’ population. In most autoimmune diseases, ther-
apy works best in patients ‘‘flaring’’ or ‘‘active’’ and at pre-
sent this is not a traditional way of viewing the progress of
pulmonary hypertension and we have no good biomarkers
to help guide us. This may affect the power of the study. In
part to address the low power issue we have adopted a
Bayesian statistical approach. Classical hypothesis testing
hinges heavily on P values and rejection of a null hypothesis
(H0). Informally, a P value measures how compatible are the
observed data with H0. In rare diseases, RCTs are always of
small size. Halsey et al.26 showed that the distribution of P
values under the alternative hypothesis (H1) in trials with
low power, e.g. 80% or less, is practically uniform regardless
of the actual biological effect. RCTs in rare diseases suffer
from low statistical power, and as we stratify our patients
more carefully this will worsen. Given these circumstances,
it may be wiser to move away from frequentist statistics and
one option is to change over to the Bayesian paradigm.
What is appealing in a Bayesian analysis is that additional
information not contained in the data (the classical statis-
tical stand) can be brought in to enlighten the results. This
approach may be of particular importance when considering
mixed populations as we have in this trial of CTD, predom-
inantly scleroderma, and IPAH where we may have signifi-
cant variation in treatment responses. The authors of this
manuscript are not frequentist or Bayesian but practical sci-
entists that can work within either paradigm. Nevertheless,
we recognize the potential benefits of using a Bayesian
approach here.
In summary, we believe that the time is right for a trial of
immunosuppression in PAH, that IL6 is an excellent start-
ing candidate, with a well-established and well-tolerated
therapy in tocilizumab. Immunosuppression is uncontrover-
sial in our opinion in CTD but more controversial in IPAH;
however, the preclinical evidence is compelling and it is now
time to test hypotheses other than vasodilation. We have
designed a small open-label investigator-led study utilizing
Bayesian statistical methods to analyze and we think this
trial design is potentially useful to the field to consider.
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